Natco Pharma Ltd.

Natco Pharma has informed that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business: To acquire 51,643,319 Shares (5,03,51,444 Ordinary Shares from public and 12,91,875 Treasury Shares/Fresh Issuance from Adcock Ingram Holdings Limited) at a cash offer of ZAR 75.00 (approximately US$ 4.27) per share i.e., 35.75% (inclusive of prior to acquisition shareholding of 0.80%) of shares of the Adcock Ingram Holdings Limited (“Adcock”), South Africa, with a total investment cost of approx. ?2000,00,00,000/- (Rupees Two Thousand Crores only) including the transaction cost and other expenses; To incorporate a wholly owned subsidiary in South Africa with an investment up to an amount not exceeding Rs.2100,00,00,000 (Rupees Two Thousand One Hundred Crores only) in the name of NATCO Pharma South Africa Proprietary Limited; To liquidate M/s. Time Cap Overseas Limited (TCOL), Wholly Owned Subsidiary of the Company and directly holds the investment in NatcoFarma do Brasil Ltda., which is a step down wholly owned subsidiary of Natco Pharma Limited. The brief disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as annexure. A Copy of Press release is also enclosed. The meeting commenced at 2.30 pm and concluded at 3.30 pm.

The above information is a part of company’s filings submitted to BSE.